INTRODUCTION
Since 1995, autologous haematopoietic SCT (AHSCT) has been used to control severe and refractory autoimmune diseases (ADs). An evolving evidence base and consensus guidelines support this treatment modality. 1 As treatment involves high-dose cytotoxic therapy, there is a potential impact on ovarian and reproductive function, affecting fertility and the ability to carry a pregnancy to full term, along with a predisposition to chemotherapy-induced menopause and the long-term consequences of oestrogen deficiency. [2] [3] [4] Although there are sporadic reports of full term pregnancy after AHSCT for ADs, 2, 3, 5, 6 there has never been any systematic study of this area. Moreover, pregnancy in patients with autoimmune diseases raises special considerations, such as treatment and monitoring of the underlying disorder during pregnancy, need and frequency of follow-up visits by specialists and influence of pregnancy on disease activity. Although AHSCT might arrest inflammatory and/or degenerative components of the autoimmune disease, uncertainties remain regarding the outcome of the pregnancy and potential flares of the AD during gestation or postpartum. Such questions are of importance as many patients with severe autoimmune diseases are young women in reproductive age with a potential desire for pregnancy, which may be influenced by control of disease activity and reduced disability following AHSCT. This AD population differs from the majority of patients that undergo AHSCT for malignancy, with exposure to a very different range of pretransplant immunosuppressive and disease modifying treatments. In addition, the underlying AD may have direct effects on the ability to conceive, relating to both reproductive function (for example, antiphospholipid antibodies) and impact of disability on sexual function.
The European Blood and Marrow Transplantation (EBMT) guidelines recommend that female patients considering AHSCT for AD should be counselled with respect to the potential effects of the procedure on the reproductive system. 1 However, there are few data to support these discussions, as the effects of both AHSCT and AD on pregnancy onset and outcome in this relatively unique group of patients have never been systematically characterized. We therefore used the databases of the EBMT and University of Sao Paulo, Ribeirão Preto, Brazil to perform a multicentre retrospective analysis of the outcomes of pregnancies following AHSCT for severe autoimmune diseases, which was the primary objective of the study. The secondary objective was to evaluate any influence of pregnancy upon the underlying autoimmune disorders.
MATERIALS AND METHODS
The study was designed as a multicentre retrospective analysis of the data available in the EBMT database ProMISE. The study was approved and conducted according to EBMT guidelines for retrospective studies. All centres that had performed AHSCT for AD were invited to participate and to report any patient who had become pregnant after AHSCT. The inclusion criteria comprised female patients aged 18 years and above undergoing AHSCT for AD between 1994 and 2011. Each centre reporting pregnancy after AHSCT for AD received a specific questionnaire (MED-C form) to capture data relating to the nature and outcome of pregnancy in terms of the maternal and foetal health, the course of the autoimmune disease throughout and beyond pregnancy and any other issues considered relevant. In order to allow an estimate of the frequency of pregnancy, all participating centres also provided their total number of female patients 18-50 years (pregnant or not) who had received AHSCT for AD as a denominator.
RESULTS
Of the 44 responding centres, 9 reported at least 1 patient who had become pregnant following AHSCT for an autoimmune disease, 30 reported no pregnancies and 5 declined to participate in the study. After centres agreed to participate, 2 additional incidences of pregnancy were identified in AD patients who had undergone AHSCT at the age of 17, which were included in the analysis.
In 324 adult female patients, 22 pregnancies were reported in 15 patients after AHSCT for AD: multiple sclerosis (MS), systemic sclerosis (SSc), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) and Takayasu's disease (TD) in the years 1997-2011, as reported in Table 1 .
Individual patient's characteristics are summarised in Table 2 . Indications for AHSCT that resulted in pregnancies included: MS-7 patients, SSc-5 patients, RA-1 patient, JIA-1 patient and TD -1 patient. The median age at diagnosis of AD was 24 years (range 14-31), 28 years at the time of AHSCT (range 17-32), and 32 years at delivery (range 20-37). All patients had received immunosuppressive +/ − cytotoxic treatment for their AD prior to mobilisation and AHSCT, as summarized in Table 3 . The stem cell mobilization protocol included CY (doses between 2 g and 5 g/m 2 ) +G-CSF in 14 patients and G-CSF alone in 1 patient. Conditioning with high dose CY (200 mg/kg) was used in 7 patients (SSc, RA or TD), BEAM (carmustine, etoposide, cytarabine, melphalan) was used in 7 patients (MS or JIA) and 1 patient received BCNU (300 mg/m 2 ) with CY (150 mg/kg) (MS). Serotherapy (anti-thymocyte globulins) was used in 11 patients. None of the patients received TBI as a part of conditioning regimen. Most patients received unmanipulated autologous grafts, but in four patients positive selection of CD34+ cells was performed. Three patients received maintenance therapy-patient 5 with glatiramer acetate, patient 7 with hydroxychloroquine sulfate and patient 11 with CYA (6 mg/kg) and mycophenolate mofetil (2 g/day) for 8 months after AHSCT.
Prior to AHSCT all 15 patients had normal menstruation and 3 successful pregnancies had occurred. Following AHSCT, menses resumed in 12 out of 15 patients after a reported delay of 3-4 months post-AHSCT. Three patients required treatment with hormone replacement therapy.
Basic characteristics and outcomes of pregnancies are shown in Table 1 . Median age at delivery was 32 (range 20-37 years) and median time from AHSCT to first successful delivery was 4 years (range 1-12 years). Four patients (two MS, one SSc and one RA) had two pregnancies, and one MS patient had four pregnancies including two natural abortions, amounting to~5% of total female patients between 18-50 years of age in the collaborating centres.
Of the 22 reported pregnancies, 20 were naturally conceived and 2 required assisted conception in the same patient 1, who required in vitro fertilisation. Fifteen pregnancies (68%) were successful, whereas seven (32%) failed due to ectopic pregnancy (n = 1), spontaneous abortion (n = 4), spontaneous foetal death (n = 1) and induced abortion (n = 1). Other adverse events included gestational diabetes mellitus (n = 1), congestive heart failure and atrial fibrillation (n = 1), hypertension (n = 1) and preterm labour Pregnancy after HSCT for autoimmune diseases EBMT ADWP E Snarski et al (n = 1). Adverse events occurred during first pregnancies and two during second pregnancies. There was no maternal mortality during pregnancy. There were 16 live births, with 1 patient having twins. Delivery was vaginal in 10 out of 22 pregnancies, with Caesarean section performed in 7 cases. There were four natural abortions (that is, miscarriages) and two induced abortions (that is, termination of pregnancy). Excluding the first trimester abortions, the median pregnancy duration was 38 weeks (range 31-42 weeks). The median birth weight of newborns was 3200 g, ranging from 1400 g to 4450 g. All newborns were otherwise healthy and we are not aware of any congenital malformations or subsequent growth and developmental abnormalities.
Exacerbations of underlying autoimmune diseases were reported in 2 patients; in patient 7 (RA) after the first pregnancy and in patient 11 (SSc) after the second pregnancy. Patient 11, whose course has been previously reported, 6 died due to worsening of systemic sclerosis with progression of skin and pulmonary fibrosis. In all other patients there were no exacerbations of autoimmune disorders related to pregnancy. At last follow-up, patients 7 (RA) and 15 (Takayasu) suffered from disease progression. In the remaining patients, the status of the underlying autoimmune disorders at last follow-up was characterized as: five patients in remission, four patients improved and three stabilized. Patient 8 (JIA) developed autoimmune haemolytic anaemia as a secondary autoimmune disease that required treatment (with corticosteroids). No secondary malignancies were reported.
DISCUSSION

Key results
This retrospective registry-based study has confirmed that pregnancy is feasible in patients who have undergone AHSCT specifically for treatment of severe autoimmune diseases. Like similar analyses in other unique disease groups, 7 it is reassuring that most pregnancies were successful and that there were no reports of birth defects or long-term developmental problems. On the basis of adverse outcome in some autoimmune diseases, such as SSc, previous recommendations have included a high degree of caution and potentially discouragement for pregnancy. 6 Disease reactivation following pregnancy occurred only in a minority of patients in the present study, and it may be reasonable to adopt a more permissive approach on a case-by-case basis, provided that close liaison and necessary supportive care is provided by relevant specialists. However, based on the numbers of patients studied, it is difficult to make any definitive statement regarding the impact of pregnancy on disease activity as the incidence of relapse after pregnancy may be within the range expected following AHSCT.
Limitations
There are a number of limitations to this study, including its retrospective nature and the possibility of the transplant centres being unaware of every single early pregnancy experienced by patients, especially those failing to achieve full-term. According to the methodology of this ADWP-EBMT retrospective study and to EBMT Good Clinical Practices Guidelines, 1 each EBMT participating center has to declare all cases of pregnancy and all female Abbreviations: AHSCT = autologous haematopoietic SCT; ATG = anti-thymocyte globulin; JIA = juvenile idiopathic arthritis; MS = multiple sclerosis; RA = rheumatoid arthritis; SSc = systemic sclerosis.
Pregnancy after HSCT for autoimmune diseases EBMT ADWP E Snarski et al patients transplanted for AD without pregnancy. The patients after AHSCT for AD constitute a small group of patients and each of them undergo careful and close follow-up at the referring centers by both haematologists and autoimmune disease specialists. It is very unlikely that the doctors in charge would be unaware of any cases of pregnancy post HSCT as: (1) the cases are rare and such a pregnancy is exceptional for the doctors; (2) female AD patients know that their pregnancies should be followed and closely consult physicians about pregnancy post HSCT. For this retrospective study on pregnancy outcome, some specific questions for data collection required further contact with the patients and had to be obtained during the clinical follow-up visits, which ranged from 4 to 17 years (median 9 years) after HSCT. The frequency of pregnancies may also be influenced by the type of autoimmune disease, patient age, education and access to contraception or assisted conception, which may vary between centres and countries. It is also not possible to establish whether there was any excess of adverse events, such as miscarriages, compared with those expected for the general population. Concerns about adverse effects might have influenced the desire for pregnancy in female patients after HSCT both prior to and after HSCT. 8 Of note, only 2 patients out of 15 from the study group already had children prior to HSCT. The retrospective design of the survey was not sufficient to determine the proportion of successful pregnancies among patients trying to become pregnant as opposed to those using contraception or sexually inactive. All these important issues should be addressed in further prospective studies.
Interpretation and prospects Interestingly, the median age for pregnancy in our cohort was 32 years. Sanders et al. noted many years ago that in aplastic anaemia patients treated with a comparable regimen of high-dose CY with ATG, loss of ovarian function was rare below the age of 26 years. However, the incidence of ovarian failure increases above this age cutoff, presumably due to the susceptibility of a progressively limited oocyte reserve. 9, 10 The most common conditioning regimens used in the patients with AD during HSCT are BEAM or high dose CY. The data on the etoposide shows impact on future fertility in young cancer patients undergoing the HSCT. 11 However, the total dose of etoposide administered for conditioning in HSCT for autoimmune diseases is much lower than in cancer patients, and the risk of suffering from impaired fertility may vary. In this regard, patients with aplastic anemia may behave similarly to patients with AD since both groups do not undergo chemotherapy prior to conditioning. In patients transplanted for severe aplastic anaemia, fertility is often preserved after conditioning with high dose CY 200 mg/kg (with or without ATG), but the effect on fertility is difficult to predict when patients are exposed to other agents, either prior to AHSCT or in conditioning regimen. 12 In our cohort, the oldest patient to become pregnant was 38 years of age, reflecting potential preservation of fertility in older patients. Therefore, individualised counselling should be provided to all females of reproductive age considering AHSCT as treatment for their autoimmune disease.
Despite its limitations, the information provided by this retrospective ADWP EBMT study will be useful for counselling female patients with respect to potential effects of the AHSCT procedure on the reproductive system, as per the EBMT ADWP current guidelines.
1 Such patients can be made aware of the possibility of conceiving post-AHSCT, and also of the need for contraception, if pregnancy were to be undesired. However, because this appears to be a relatively rare event in our population, if future pregnancies are desired, potential female candidates should be offered specific strategies such as embryo or oocyte cryopreservation as potential back-up in case reproductive function is compromised or lost following AHSCT. In cases of pregnancy, continuous monitoring of these high risk patients, from conception to delivery, should be offered in expert centres with multidisciplinary regular follow-up offered to mother and child and adequate reporting of cases in the EBMT dedicated registry.
